Skip Header

Contribute Send feedback
Read comments (?) or add your own

Q05823 (RN5A_HUMAN) Reviewed, UniProtKB/Swiss-Prot

Last modified January 25, 2012. Version 114. Feed History...

Clusters with 100%, 90%, 50% identity | Documents (7) | Third-party data text xml rdf/xml gff fasta
to top of pageNames·Attributes·General annotation·Ontologies·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize order

Names and origin

Protein namesRecommended name:
2-5A-dependent ribonuclease

Short name=2-5A-dependent RNase
EC=3.1.26.-
Alternative name(s):
Ribonuclease 4
Ribonuclease L
Short name=RNase L
Gene names
Name:RNASEL
Synonyms:RNS4
OrganismHomo sapiens (Human)
Taxonomic identifier9606 [NCBI]
Taxonomic lineageEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiMammaliaEutheriaEuarchontogliresPrimatesHaplorrhiniCatarrhiniHominidaeHomo

Protein attributes

Sequence length741 AA.
Sequence statusComplete.
Protein existenceEvidence at protein level

General annotation (Comments)

Function

Endoribonuclease that functions in the interferon (IFN) antiviral response. In INF treated and virus infected cells, RNASEL probably mediates its antiviral effects through a combination of direct cleavage of single-stranded viral RNAs, inhibition of protein synthesis through the degradation of rRNA, induction of apoptosis, and induction of other antiviral genes. RNASEL mediated apoptosis is the result of a JNK-dependent stress-response pathway leading to cytochrome c release from mitochondria and caspase-dependent apoptosis. Therefore, activation of RNASEL could lead to elimination of virus infected cells under some circumstances. Might play a central role in the regulation of mRNA. turnover. Ref.5

Catalytic activity

Cleaves 3' of UpNp dimers, with preference for UU and UA sequences, to sets of discrete products ranging from between 4 and 22 nucleotides in length.

Cofactor

Manganese or magnesium. Required for optimal RNA cleavage rates.

Enzyme regulation

After binding to 2-5A (5'-phosphorylated 2',5'-linked oligoadenylates) the homodimerization and subsequent activation occurs. Inhibited by RNASEL inhibitor ABCE1/RLI, a cytoplasmic member of the ATP-binding cassette (ABC) transporter family.

Subunit structure

Monomer (inactive form) or homodimer. Interacts with ABCE1; this interaction inhibits the RNASEL. Ref.4

Subcellular location

Cytoplasm. Mitochondrion Ref.5.

Tissue specificity

Highly expressed in spleen and thymus followed by prostate, testis, uterus, small intestine, colon and peripheral blood leukocytes.

Induction

By interferons. Virus replication in higher vertebrates is restrained by IFNs that cause cells to transcribe genes encoding antiviral proteins, such as 2'-5' oligoadenylate synthetases (OASs). oligoadenylate synthetase is stimulated by dsRNA to produce 5'-phosphorylated, 2'-5'-linked oligoadenylates (2-5A), whose function is to activate RNASEL.

Domain

The nine ankyrin repeats also called 2-5A sensor constitute the N-terminus 2-5A binding domain.

The protein kinase domain is predicted to be catalytically inactive. It allows the homodimerization.

The ribonuclease domain is located in the C-terminus. A single active nuclease domain in a dimer is sufficient for ribonuclease activity By similarity.

Involvement in disease

Defects in RNASEL are a cause of susceptibility to prostate cancer hereditary type 1 (HPC1) [MIM:601518]. It is a condition associated with familial predisposition to cancer of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

Sequence similarities

Belongs to the protein kinase superfamily.

Contains 9 ANK repeats.

Contains 1 KEN domain.

Contains 1 protein kinase domain.

Sequence annotation (Features)

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifier

Molecule processing

Chain1 – 7417412-5A-dependent ribonuclease
PRO_0000067051

Regions

Repeat24 – 5330ANK 1
Repeat58 – 8730ANK 2
Repeat91 – 12030ANK 3
Repeat124 – 15330ANK 4
Repeat167 – 19731ANK 5
Repeat201 – 23434ANK 6
Repeat238 – 26831ANK 7
Repeat272 – 30130ANK 8
Repeat303 – 32927ANK 9
Domain365 – 586222Protein kinase
Domain589 – 723135KEN
Zinc finger395 – 44450C6-type; atypical
Region229 – 242142-5A binding (P-loop) 1
Region253 – 275232-5A binding (P-loop) 2

Amino acid modifications

Modified residue6841N6-acetyllysine Ref.10

Natural variations

Natural variant591G → S. Ref.12 Ref.13
VAR_013509
Natural variant971I → L. Ref.15
Corresponds to variant rs56250729 [ dbSNP | Ensembl ].
VAR_042358
Natural variant2891A → T. Ref.15
Corresponds to variant rs35553278 [ dbSNP | Ensembl ].
VAR_042359
Natural variant4061S → F. Ref.12
VAR_013510
Natural variant4621R → Q Risk factor for prostate cancer; reduced enzymatic activity. Ref.12 Ref.13 Ref.14 Ref.15
Corresponds to variant rs486907 [ dbSNP | Ensembl ].
VAR_012056
Natural variant5411D → E No change in enzymatic activity. Ref.12 Ref.13 Ref.14 Ref.15
Corresponds to variant rs627928 [ dbSNP | Ensembl ].
VAR_012057
Natural variant5921R → H. Ref.15
Corresponds to variant rs35896902 [ dbSNP | Ensembl ].
VAR_042360

Experimental info

Mutagenesis2401K → N: Reduced 2-5A binding activity; almost complete loss of 2-5A binding activity; when associated with N-274. Ref.1
Mutagenesis2741K → N: Reduced 2-5A binding activity; almost complete loss of 2-5A binding activity; when associated with N-240. Ref.1
Mutagenesis3921K → R: Complete loss of enzymatic activity and enzyme dimerization. No change in binding to 2-5A and RNA. Ref.8
Mutagenesis5831H → A: No change in enzymatic activity. Ref.9
Mutagenesis5841P → A: No change in enzymatic activity. Ref.9
Mutagenesis6321W → A: No change in enzymatic activity. Ref.9
Mutagenesis6611D → A: Complete loss of enzymatic activity. Ref.9
Mutagenesis6671R → A: Complete loss of enzymatic activity. No change in 2-5A binding and enzyme dimerization. Ref.9
Mutagenesis6721H → A: Complete loss of enzymatic activity. No change in 2-5A binding activity and enzyme dimerization. Ref.9

Secondary structure

....................................... 741
Helix Strand Turn

Details...

Sequences

Sequence LengthMass (Da)Tools
Q05823 [UniParc].

Last modified February 1, 1996. Version 2.
Checksum: 91385EA307E3CE1D

FASTA74183,533
        10         20         30         40         50         60 
MESRDHNNPQ EGPTSSSGRR AAVEDNHLLI KAVQNEDVDL VQQLLEGGAN VNFQEEEGGW 

        70         80         90        100        110        120 
TPLHNAVQMS REDIVELLLR HGADPVLRKK NGATPFILAA IAGSVKLLKL FLSKGADVNE 

       130        140        150        160        170        180 
CDFYGFTAFM EAAVYGKVKA LKFLYKRGAN VNLRRKTKED QERLRKGGAT ALMDAAEKGH 

       190        200        210        220        230        240 
VEVLKILLDE MGADVNACDN MGRNALIHAL LSSDDSDVEA ITHLLLDHGA DVNVRGERGK 

       250        260        270        280        290        300 
TPLILAVEKK HLGLVQRLLE QEHIEINDTD SDGKTALLLA VELKLKKIAE LLCKRGASTD 

       310        320        330        340        350        360 
CGDLVMTARR NYDHSLVKVL LSHGAKEDFH PPAEDWKPQS SHWGAALKDL HRIYRPMIGK 

       370        380        390        400        410        420 
LKFFIDEKYK IADTSEGGIY LGFYEKQEVA VKTFCEGSPR AQREVSCLQS SRENSHLVTF 

       430        440        450        460        470        480 
YGSESHRGHL FVCVTLCEQT LEACLDVHRG EDVENEEDEF ARNVLSSIFK AVQELHLSCG 

       490        500        510        520        530        540 
YTHQDLQPQN ILIDSKKAAH LADFDKSIKW AGDPQEVKRD LEDLGRLVLY VVKKGSISFE 

       550        560        570        580        590        600 
DLKAQSNEEV VQLSPDEETK DLIHRLFHPG EHVRDCLSDL LGHPFFWTWE SRYRTLRNVG 

       610        620        630        640        650        660 
NESDIKTRKS ESEILRLLQP GPSEHSKSFD KWTTKINECV MKKMNKFYEK RGNFYQNTVG 

       670        680        690        700        710        720 
DLLKFIRNLG EHIDEEKHKK MKLKIGDPSL YFQKTFPDLV IYVYTKLQNT EYRKHFPQTH 

       730        740 
SPNKPQCDGA GGASGLASPG C 

« Hide

References

« Hide 'large scale' references
[1]"Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action."
Zhou A., Hassel B.A., Silverman R.H.
Cell 72:753-765(1993) [PubMed: 7680958] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA], MUTAGENESIS OF LYS-240 AND LYS-274.
Tissue: Kidney.
[2]"Analysis and origins of the human and mouse RNase L genes: mediators of interferon action."
Zhou A., Nie H., Silverman R.H.
Mamm. Genome 11:989-992(2000) [PubMed: 11063255] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA].
Tissue: Placenta.
[3]"Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase."
Dong B., Xu L., Zhou A., Hassel B.A., Lee X., Torrence P.F., Silverman R.H.
J. Biol. Chem. 269:14153-14158(1994) [PubMed: 7514601] [Abstract]
Cited for: CHARACTERIZATION OF RNASEL ACTIVITY.
[4]"Cloning and characterization of a RNase L inhibitor. A new component of the interferon-regulated 2-5A pathway."
Bisbal C., Martinand C., Silhol M., Lebleu B., Salehzada T.
J. Biol. Chem. 270:13308-13317(1995) [PubMed: 7539425] [Abstract]
Cited for: INTERACTION WITH ABCE1.
[5]"The 2-5A/RNase L/RNase L inhibitor (RNI) pathway regulates mitochondrial mRNAs stability in interferon alpha-treated H9 cells."
Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B., Salehzada T.
J. Biol. Chem. 276:48473-48482(2001) [PubMed: 11585831] [Abstract]
Cited for: FUNCTION, SUBCELLULAR LOCATION.
[6]Erratum
Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B., Salehzada T.
J. Biol. Chem. 277:13354-13354(2002)
[7]"The 2-5A system in viral infection and apoptosis."
Castelli J., Wood K.A., Youle R.J.
Biomed. Pharmacother. 52:386-390(1998) [PubMed: 9856285] [Abstract]
Cited for: REVIEW.
[8]"Alternative function of a protein kinase homology domain in 2', 5'-oligoadenylate dependent RNase L."
Dong B., Silverman R.H.
Nucleic Acids Res. 27:439-445(1999) [PubMed: 9862963] [Abstract]
Cited for: MUTAGENESIS OF LYS-392.
[9]"Basis for regulated RNA cleavage by functional analysis of RNase L and Ire1p."
Dong B., Niwa M., Walter P., Silverman R.H.
RNA 7:361-373(2001) [PubMed: 11333017] [Abstract]
Cited for: MUTAGENESIS OF HIS-583; PRO-584; TRP-632; ASP-661; ARG-667 AND HIS-672.
[10]"Lysine acetylation targets protein complexes and co-regulates major cellular functions."
Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T., Olsen J.V., Mann M.
Science 325:834-840(2009) [PubMed: 19608861] [Abstract]
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-684, MASS SPECTROMETRY.
[11]"Structural basis for recognition of 2',5'-linked oligoadenylates by human ribonuclease L."
Tanaka N., Nakanishi M., Kusakabe Y., Goto Y., Kitade Y., Nakamura K.T.
EMBO J. 23:3929-3938(2004) [PubMed: 15385955] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-305 IN COMPLEX WITH THE ACTIVATOR 2-5A.
[12]"Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer."
Roekman A., Ikonen T., Seppaelae E.H., Nupponen N., Autio V., Mononen N., Bailey-Wilson J., Trent J., Carpten J., Matikainen M.P., Koivisto P.A., Tammela T.L.J., Kallioniemi O.-P., Schleutker J.
Am. J. Hum. Genet. 70:1299-1304(2002) [PubMed: 11941539] [Abstract]
Cited for: VARIANTS SER-59; PHE-406; GLN-462 AND GLU-541.
[13]"Germline mutations in the ribonuclease L gene in families showing linkage with HPC1."
Carpten J., Nupponen N., Isaacs S., Sood R., Robbins C., Xu J., Faruque M., Moses T., Ewing C., Gillanders E., Hu P., Bujnovszky P., Makalowska I., Baffoe-Bonnie A., Faith D., Smith J., Stephan D., Wiley K. expand/collapse author list , Brownstein M., Gildea D., Kelly B., Jenkins R., Hostetter G., Matikainen M., Schleutker J., Klinger K., Connors T., Xiang Y., Wang Z., De Marzo A., Papadopoulos N., Kallioniemi O.-P., Burk R., Meyers D., Groenberg H., Meltzer P., Silverman R., Bailey-Wilson J., Walsh P., Isaacs W., Trent J.
Nat. Genet. 30:181-184(2002) [PubMed: 11799394] [Abstract]
Cited for: VARIANTS SER-59; GLN-462 AND GLU-541.
[14]"RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases."
Casey G., Neville P.J., Plummer S.J., Xiang Y., Krumroy L.M., Klein E.A., Catalona W.J., Nupponen N., Carpten J.D., Trent J.M., Silverman R.H., Witte J.S.
Nat. Genet. 32:581-583(2002) [PubMed: 12415269] [Abstract]
Cited for: CHARACTERIZATION OF VARIANTS GLN-462 AND GLU-541.
[15]"Patterns of somatic mutation in human cancer genomes."
Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G. expand/collapse author list , Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.
Nature 446:153-158(2007) [PubMed: 17344846] [Abstract]
Cited for: VARIANTS [LARGE SCALE ANALYSIS] LEU-97; THR-289; GLN-462; GLU-541 AND HIS-592.
+Additional computationally mapped references.

Cross-references

Sequence databases

EMBL
GenBank
DDBJ
L10381 Genomic DNA. Translation: AAA18032.1.
IPIIPI00015864.
PIRA45771.
RefSeqNP_066956.1. NM_021133.3.
UniGeneHs.518545.

3D structure databases

PDBe
RCSB PDB
PDBj
EntryMethodResolution (Å)ChainPositionsPDBsum
1WDYX-ray1.80A21-305[»]
ProteinModelPortalQ05823.
SMRQ05823. Positions 21-332, 357-722.
ModBaseSearch...

Protein-protein interaction databases

STRINGQ05823.

PTM databases

PhosphoSiteQ05823.

Polymorphism databases

DMDM1350802.

Proteomic databases

PeptideAtlasQ05823.
PRIDEQ05823.

Protocols and materials databases

StructuralBiologyKnowledgebaseSearch...

Genome annotation databases

EnsemblENST00000367559; ENSP00000356530; ENSG00000135828.
ENST00000444138; ENSP00000411147; ENSG00000135828.
GeneID6041.
KEGGhsa:6041.
UCSCuc001gpj.1. human.

Organism-specific databases

CTD6041.
GeneCardsGC01M182542.
H-InvDBHIX0028845.
HGNCHGNC:10050. RNASEL.
HPACAB010906.
HPA002633.
MIM176807. phenotype.
180435. gene.
601518. phenotype.
neXtProtNX_Q05823.
Orphanet1331. Familial prostate cancer.
PharmGKBPA34418.
GenAtlasSearch...

Phylogenomic databases

eggNOGprNOG04117.
HOGENOMHBG280468.
HOVERGENHBG012673.
InParanoidQ05823.
OMANMGRNAL.
OrthoDBEOG479F6R.
PhylomeDBQ05823.

Enzyme and pathway databases

ReactomeREACT_6900. Immune System.

Gene expression databases

ArrayExpressQ05823.
BgeeQ05823.
CleanExHS_RNASEL.
GenevestigatorQ05823.
GermOnlineENSG00000135828. Homo sapiens.

Family and domain databases

InterProIPR002110. Ankyrin_rpt.
IPR020683. Ankyrin_rpt-contain_dom.
IPR010513. KEN_RNase_activator.
IPR011009. Kinase-like_dom.
IPR000719. Prot_kinase_cat_dom.
IPR006567. PUG-dom.
IPR017442. Se/Thr_kinase-like_dom.
[Graphical view]
Gene3DG3DSA:1.25.40.20. ANK. 1 hit.
KOK01165.
PfamPF00023. Ank. 4 hits.
PF12796. Ank_2. 1 hit.
PF00069. Pkinase. 1 hit.
PF06479. Ribonuc_2-5A. 1 hit.
[Graphical view]
PRINTSPR01415. ANKYRIN.
SMARTSM00248. ANK. 8 hits.
SM00580. PUG. 1 hit.
[Graphical view]
SUPFAMSSF48403. ANK. 1 hit.
SSF56112. Kinase_like. 1 hit.
PROSITEPS50297. ANK_REP_REGION. 1 hit.
PS50088. ANK_REPEAT. 6 hits.
PS51392. KEN. 1 hit.
PS00107. PROTEIN_KINASE_ATP. False negative.
PS50011. PROTEIN_KINASE_DOM. 1 hit.
[Graphical view]
ProtoNetSearch...

Other

NextBio23543.
PMAP-CutDBQ05823.
SOURCESearch...

Entry information

Entry nameRN5A_HUMAN
AccessionPrimary (citable) accession number: Q05823
Entry history
Integrated into UniProtKB/Swiss-Prot: November 1, 1995
Last sequence update: February 1, 1996
Last modified: January 25, 2012
This is version 114 of the entry and version 2 of the sequence. [Complete history]
Entry statusReviewed (UniProtKB/Swiss-Prot)
Annotation programChordata Protein Annotation Program
DisclaimerAny medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.

Relevant documents

Human and mouse protein kinases

Human and mouse protein kinases: classification and index

Human chromosome 1

Human chromosome 1: entries, gene names and cross-references to MIM

Human entries with polymorphisms or disease mutations

List of human entries with polymorphisms or disease mutations

Human polymorphisms and disease mutations

Index of human polymorphisms and disease mutations

MIM cross-references

Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot

PDB cross-references

Index of Protein Data Bank (PDB) cross-references

SIMILARITY comments

Index of protein domains and families